Abstract
The surface properties of blood lymphocytes from treated myeloma patients and healthy controls were studied in vitro. The patients were tested 6 weeks after the last treatment to allow time for cells to recovery from possible drug toxicity. Peripheral-blood lymphocytes were tested for rosette formation with unsensitized sheep erythrocytes (E rosettes) and with complement and antibody-coated erythrocytes (EAC rosettes). The tests were duplicated using lymphocytes pretreated with trypsin. As others have noted, myelomatosis is associated with increased blood levels of EAC-rosette-forming cells and a marked reduction in E-rosette-forming cells. E-rosette formation was significantly increased by pretreatment of myeloma lymphocytes with trypsin. By contrast, enzyme-treated cells showed no significant change in EAC-rosette formation. These results suggest that the absolute number of circulating T cells is probably not reduced in myelomatosis, but that the surface of T cells is somehow modified so that a proportion of them lose the ability to form E rosettes.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azam L., Delamore I. W. Combination therapy for myelomatosis. Br Med J. 1974 Dec 7;4(5944):560–564. doi: 10.1136/bmj.4.5944.560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bianco C., Patrick R., Nussenzweig V. A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med. 1970 Oct 1;132(4):702–720. doi: 10.1084/jem.132.4.702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Galili U., Schlesinger M. The formation of stable E rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells. J Immunol. 1974 May;112(5):1628–1634. [PubMed] [Google Scholar]
- Han T., Minowada J. Enhanced E- and EAC-rosette formation by neuraminidase. J Immunol Methods. 1976;12(3-4):253–260. doi: 10.1016/0022-1759(76)90046-6. [DOI] [PubMed] [Google Scholar]
- Jondal M., Holm G., Wigzell H. Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972 Aug 1;136(2):207–215. doi: 10.1084/jem.136.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones S. V., McFarlane H. T and B cells in myelomatosis. Br J Haematol. 1975 Dec;31(4):545–552. doi: 10.1111/j.1365-2141.1975.tb00889.x. [DOI] [PubMed] [Google Scholar]
- Mellstedt H., Holm G. In vitro studies of lymphocytes from patients with plasma cell myeloma. I. Stimulation by mitogens and cytotoxic activities. Clin Exp Immunol. 1973 Nov;15(3):309–320. [PMC free article] [PubMed] [Google Scholar]
- Mellstedt H., Jondal M., Holm G. In vitro studies of lymphocytes from patients with plasma cell myeloma. II. Characterization by cell surface markers. Clin Exp Immunol. 1973 Nov;15(3):321–330. [PMC free article] [PubMed] [Google Scholar]
- Minowada J., Onuma T., Moore G. E. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst. 1972 Sep;49(3):891–895. [PubMed] [Google Scholar]
- Mortensen R. F., Osmand A. P., Gewurz H. Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med. 1975 Apr 1;141(4):821–839. [PMC free article] [PubMed] [Google Scholar]
- Nemoto T., Han T., Minowada J., Angkur V., Chamberlain A., Dao L. Cell-mediated immune status of breast cancer patients: evaluation by skin tests, lymphocyte stimulation, and counts of rosette-forming cells. J Natl Cancer Inst. 1974 Sep;53(3):641–645. doi: 10.1093/jnci/53.3.641. [DOI] [PubMed] [Google Scholar]
- Wybran J., Carr M. C., Fudenberg H. H. The human rosette-forming cell as a marker of a population of thymus-derived cells. J Clin Invest. 1972 Oct;51(10):2537–2543. doi: 10.1172/JCI107069. [DOI] [PMC free article] [PubMed] [Google Scholar]